First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis

INTRODUCTION: Sorafenib was historically the standard of care for advanced hepatocellular carcinoma (aHCC) until it was superseded by the combination of atezolizumab and bevacizumab. Thereafter, several novel first-line combination therapies have demonstrated favorable outcomes. The efficacies of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Fong, Khi Yung, Zhao, Joseph Jonathan, Sultana, Rehena, Lee, Joycelyn Jie Xin, Lee, Suat Ying, Chan, Stephen Lam, Yau, Thomas, Tai, David Wai Meng, Sundar, Raghav, Too, Chow Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982345/
https://www.ncbi.nlm.nih.gov/pubmed/36872922
http://dx.doi.org/10.1159/000526639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982345/
https://www.ncbi.nlm.nih.gov/pubmed/36872922
http://dx.doi.org/10.1159/000526639

Ejemplares similares